Milner Daiichi Sankyo Event: Precision Drug Delivery

The Milner Therapeutics Institute is pleased to welcome colleagues from Daiichi Sankyo for an afternoon focused on precision drug delivery and opportunities for research collaboration.

This event will provide a unique opportunity to meet members of Daiichi Sankyo's European team and introduce them to research expertise and capabilities from across the Cambridge ecosystem.

Senior colleagues from the Daiichi Sankyo Research Institute Munich will present the company's current research focus and priorities for external research collaboration, with a particular emphasis on technologies underpinning precision drug delivery in oncology, cardiovascular disease and beyond.

The afternoon will include presentations from Daiichi Sankyo, networking and opportunities to meet 1:1 with Daiichi Sankyo colleagues to discuss potential areas for partnership and collaboration.

Who should attend?

This event is open to academics, clinician scientists and biotechnology companies working in research areas relevant to Daiichi Sankyo.

Programme

14:00 – Welcome and presentations:

• Daiichi Sankyo Corporate Introduction – Better Together
  Benjamin August, PhD; Senior Director, Search & Evaluation - Research & Technologies
  
• Daiichi Sankyo: Our Science and Technology
  Masakazu Hirouchi, PhD; Specialty Medicine Lead, DS Research Institute Munich
  
• Daiichi Sankyo Research Institute Munich Vision and Areas of Interest
  Masakatsu Suzuki, PhD; Head of DS Research Institute Munich

15:30 – Networking session

16:15 – 17:45 – 1:1 meetings between attendees and Daiichi Sankyo team

Scientific topics will include:

• Oncology with ADC technology
• Drug Delivery Technologies for nucleic acids (LNP platform for mRNA vaccine delivery as an example)
• Outlook: Modalities of interest for different therapy areas

Limited places - Registration is free and required to attend.

If you are interested in a 1:1 meeting with Daiichi Sankyo colleagues, please indicate this during registration and provide brief details of the area of research, technology or potential collaboration you would like to discuss.

About Daiichi Sankyo

Daiichi Sankyo is a global healthcare company with a strategic focus on oncology. The company is advancing an industry-leading antibody drug conjugate portfolio, alongside identifying breakthrough technologies with the potential to deliver practice-changing medicines to patients, healthcare professionals and society.

Venue accessibility.